» Articles » PMID: 15870674

Epidemiology of Cystic Fibrosis-related Diabetes

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2005 May 5
PMID 15870674
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Cystic fibrosis-related diabetes (CFRD) has emerged as an important complication of CF. To better understand who is at risk of developing CFRD, to gain insight into the impact of CFRD on pulmonary and nutritional status, and to assess the association of CFRD with various practice patterns and comorbid conditions, we characterized the Epidemiologic Study of Cystic Fibrosis (ESCF) patient population.

Study Design: Analyses were performed on the 8247 adolescents and adults who were evaluated at one of 204 participating sites during 1998. CFRD was defined as the use of insulin or an oral hypoglycemic agent at any time during the year.

Results: Previously reported risk factors for CFRD including age, gender (female), and pancreatic insufficiency were confirmed in this study. Patients with CFRD had more severe pulmonary disease, more frequent pulmonary exacerbations, and poorer nutritional status as compared with those without diabetes. CFRD also was associated with liver disease.

Conclusions: CFRD is a common complication in adolescents and adults that is associated with more severe disease.

Citing Articles

A cross-sectional study in adiponectin, glucose metabolism, and body composition in cystic fibrosis.

Nielsen B, Mikkelsen C, Oturai P, Krogh-Madsen R, Katzenstein T, Ritz C Front Endocrinol (Lausanne). 2024; 15:1382241.

PMID: 39530118 PMC: 11550925. DOI: 10.3389/fendo.2024.1382241.


Evaluation of Oral Glucose Tolerance Test Results in Children with Cystic Fibrosis.

Bestas A, Unal E, Aktar Karakaya A, Beyazit N, Savas S, Sen V Sisli Etfal Hastan Tıp Bul. 2024; 58(3):389-394.

PMID: 39411039 PMC: 11472201. DOI: 10.14744/SEMB.2024.65983.


Insulin sensitivity, disposition index and insulin clearance in cystic fibrosis: a cross-sectional study.

Nielsen B, Mathiesen I, Krogh-Madsen R, Katzenstein T, Pressler T, Shaw J Diabetologia. 2024; 67(10):2188-2198.

PMID: 39093413 PMC: 11447061. DOI: 10.1007/s00125-024-06220-6.


Advances in diabetes technology to improve the lives of people with cystic fibrosis.

Scully K, Marks B, Putman M Diabetologia. 2024; 67(10):2143-2153.

PMID: 38995399 DOI: 10.1007/s00125-024-06223-3.


Racial inequities and rare variants: Impact on cystic fibrosis diagnosis and treatment.

Wu M, Davis J, Zhao C, Daley T, Oliver K J Clin Transl Endocrinol. 2024; 36:100344.

PMID: 38765466 PMC: 11099334. DOI: 10.1016/j.jcte.2024.100344.